IFNA-AS1 regulates CD4+ T cell activation in myasthenia gravis though HLA-DRB1

Clinical Immunology

Volumn 183, Issue , 2017, Pages 121-131

  Luo, Mengchuan ^a   Liu, Xiaofang ^a   Meng, Huanyu ^a   Xu, Liqun ^a   Li, Yi ^a   Li, Zhibin ^a   Liu, Chang ^a   Luo, Yue Bei ^a   Hu, Bo ^a   Xue, Yuanyuan ^a   Liu, Yu ^a   Luo, Zhaohui ^a   Yang, Huan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CD4+; HLA DOB; HLA DRB1; IFNG AS1; Long non coding RNAs (lncRNAs); Myasthenia gravis

Indexed keywords

CD40 LIGAND; HLA D ANTIGEN; HLA DRB1 ANTIGEN; HLA-DO ANTIGENS; LONG NON-CODING RNA IFNA-AS1, HUMAN; LONG UNTRANSLATED RNA;

ADOLESCENT; ADULT; ANIMAL; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MOUSE; MYASTHENIA GRAVIS; REGULATORY T LYMPHOCYTE; TH1 CELL; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELL PROLIFERATION; FEMALE; HLA-D ANTIGENS; HLA-DRB1 CHAINS; HUMANS; MALE; MICE; MIDDLE AGED; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RNA, LONG NONCODING; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; YOUNG ADULT;

EID: 85028037058     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2017.08.008     Document Type: Article

References (43)

1. Berrih-Aknin, S., Frenkian-Cuvelier, M., Eymard, B., Diagnostic and clinical classification of autoimmune myasthenia gravis. J. Autoimmun. 48-49 (2014), 143–148.
2. Berrih-Aknin, S., Le Panse, R., Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J. Autoimmun. 52 (2014), 90–100.
3. Le Panse, R., Berrih-Aknin, S., Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation. Curr. Opin. Neurol. 26 (2013), 569–576.
4. Liu, X.F., Wang, R.Q., Hu, B., Luo, M.C., Zeng, Q.M., Zhou, H., Huang, K., Dong, X.H., Luo, Y.B., Luo, Z.H., Yang, H., MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10. Clin. Immunol. 164 (2016), 106–113.
5. Im, S.H., Barchan, D., Maiti, P.K., Fuchs, S., Souroujon, M.C., Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J. Immunol. 166 (2001), 6893–6898.
6. Necsulea, A., Soumillon, M., Warnefors, M., Liechti, A., Daish, T., Zeller, U., Baker, J.C., Grutzner, F., Kaessmann, H., The evolution of lncRNA repertoires and expression patterns in tetrapods. Nature 505 (2014), 635–640.
7. Wan, G., Hu, X., Liu, Y., Han, C., Sood, A.K., Calin, G.A., Zhang, X., Lu, X., A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO J. 32 (2013), 2833–2847.
8. Mercer, T.R., Dinger, M.E., Sunkin, S.M., Mehler, M.F., Mattick, J.S., Specific expression of long noncoding RNAs in the mouse brain. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 716–721.
9. Ponjavic, J., Oliver, P.L., Lunter, G., Ponting, C.P., Genomic and transcriptional co-localization of protein-coding and long non-coding RNA pairs in the developing brain. PLoS Genet., 5, 2009, e1000617.
10. Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., Huarte, M., Zuk, O., Carey, B.W., Cassady, J.P., Cabili, M.N., Jaenisch, R., Mikkelsen, T.S., Jacks, T., Hacohen, N., Bernstein, B.E., Kellis, M., Regev, A., Rinn, J.L., Lander, E.S., Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458 (2009), 223–227.
11. Lin, D., Pestova, T.V., Hellen, C.U., Tiedge, H., Translational control by a small RNA: dendritic BC1 RNA targets the eukaryotic initiation factor 4A helicase mechanism. Mol. Cell. Biol. 28 (2008), 3008–3019.
12. Khalil, A.M., Faghihi, M.A., Modarresi, F., Brothers, S.P., Wahlestedt, C., A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS One, 3, 2008, e1486.
13. Lee, D.Y., Moon, J., Lee, S.T., Jung, K.H., Park, D.K., Yoo, J.S., Sunwoo, J.S., Byun, J.I., Shin, J.W., Jeon, D., Jung, K.Y., Kim, M., Lee, S.K., Chu, K., Distinct expression of long non-coding RNAs in an Alzheimer's disease model. J. Alzheimers Dis. 45 (2015), 837–849.
14. Riva, P., Ratti, A., Venturin, M., The long non-coding RNAs in neurodegenerative diseases: novel mechanisms of pathogenesis. Curr. Alzheimer Res. 13 (2016), 1219–1231.
15. Sunwoo, J.S., Lee, S.T., Im, W., Lee, M., Byun, J.I., Jung, K.H., Park, K.I., Jung, K.Y., Lee, S.K., Chu, K., Kim, M., Altered expression of the long noncoding RNA NEAT1 in huntington's disease. Mol. Neurobiol., 2016.
16. Millar, J.K., Wilson-Annan, J.C., Anderson, S., Christie, S., Taylor, M.S., Semple, C.A., Devon, R.S., Clair, D.M. St, Muir, W.J., Blackwood, D.H., Porteous, D.J., Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 9 (2000), 1415–1423.
17. Martinez, R., Martin-Subero, J.I., Rohde, V., Kirsch, M., Alaminos, M., Fernandez, A.F., Ropero, S., Schackert, G., Esteller, M., A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4 (2009), 255–264.
18. Luo, Z., Li, Y., Liu, X., Luo, M., Xu, L., Luo, Y., Xiao, B., Yang, H., Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes. BMC Med. Genet., 8, 2015, 13.
19. Vigneau, S., Rohrlich, P.S., Brahic, M., Bureau, J.F., Tmevpg1, a candidate gene for the control of Theiler's virus persistence, could be implicated in the regulation of gamma interferon. J. Virol. 77 (2003), 5632–5638.
20. Gomez, J.A., Wapinski, O.L., Yang, Y.W., Bureau, J.F., Gopinath, S., Monack, D.M., Chang, H.Y., Brahic, M., Kirkegaard, K., The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-gamma locus. Cell 152 (2013), 743–754.
21. Goris, A., Heggarty, S., Marrosu, M.G., Graham, C., Billiau, A., Vandenbroeck, K., Linkage disequilibrium analysis of chromosome 12q14-15 in multiple sclerosis: delineation of a 118-kb interval around interferon-gamma (IFNG) that is involved in male versus female differential susceptibility. Genes Immun. 3 (2002), 470–476.
22. Collier, S.P., Collins, P.L., Williams, C.L., Boothby, M.R., Aune, T.M., Cutting edge: influence of Tmevpg1, a long intergenic noncoding RNA, on the expression of Ifng by Th1 cells. J. Immunol. 189 (2012), 2084–2088.
23. Collier, S.P., Henderson, M.A., Tossberg, J.T., Aune, T.M., Regulation of the Th1 genomic locus from Ifng through Tmevpg1 by T-bet. J. Immunol. 193 (2014), 3959–3965.
24. Katzberg, H.D., Barnett, C., Merkies, I.S., Bril, V., Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve 49 (2014), 661–665.
25. Wu, B., Goluszko, E., Huda, R., Tuzun, E., Christadoss, P., Coligan, John E., et al. (eds.) Experimental autoimmune myasthenia gravis in the mouse, Current protocols in immunology, 2011, 23 Unit 15. (Chapter 15).
26. Wu, B., Goluszko, E., Huda, R., Tuzun, E., Christadoss, P., Coligan, John E., et al. (eds.) Experimental autoimmune myasthenia gravis in the mouse, Current protocols in immunology, 2013, 18 Chapter 15. Unit 15.
27. Avidan, N., Le Panse, R., Berrih-Aknin, S., Miller, A., Genetic basis of myasthenia gravis - a comprehensive review. J. Autoimmun. 52 (2014), 146–153.
28. Cavalli, G., Hayashi, M., Jin, Y., Yorgov, D., Santorico, S.A., Holcomb, C., Rastrou, M., Erlich, H., Tengesdal, I.W., Dagna, L., Neff, C.P., Palmer, B.E., Spritz, R.A., Dinarello, C.A., MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 1363–1368.
29. Liu, X.F., Luo, Y.B., Luo, Z.H., Yang, H., Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs. Neurochem. Res. 39 (2014), 1661–1674.
30. Hoffmann, S., Siedler, J., Brandt, A.U., Piper, S.K., Kohler, S., Sass, C., Paul, F., Reilmann, R., Meisel, A., Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. BMC Neurol., 15, 2015, 265.
31. Guptill, J.T., Soni, M., Meriggioli, M.N., Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics 13 (2016), 118–131.
32. Higham, E.M., Wittrup, K.D., Chen, J., Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8 + T cells engineered to express CD40 ligand. J. Immunol. 184 (2010), 3394–3400.
33. Kato-Kogoe, N., Ohyama, H., Nishimura, F., Meguro, M., Yoshizawa, S., Okada, Y., Nakasho, K., Yamanegi, K., Yamada, N., Hata, M., Higashi, T., Terada, N., Matsushita, S., Fibroblasts stimulated via HLA-II molecules produce prostaglandin E(2) and regulate cytokine production from helper T cells. Lab. Investig. 90 (2010), 1747–1756.
34. De Lerma Barbaro, A., De Ambrosis, A., Banelli, B., Li Pira, G., Aresu, O., Romani, M., Ferrini, S., Accolla, R.S., Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-gamma in promyelocytic cells. Int. Immunol. 20 (2008), 1457–1466.
35. Adams, E.J., Luoma, A.M., The adaptable major histocompatibility complex (MHC) fold: structure and function of nonclassical and MHC class I-like molecules. Annu. Rev. Immunol. 31 (2013), 529–561.
36. Kajikawa, M., Kasahara, M., Structure and function of non-classical MHC class I molecules. Seikagaku 81 (2009), 189–199.
37. Guce, A.I., Mortimer, S.E., Yoon, T., Painter, C.A., Jiang, W., Mellins, E.D., Stern, L.J., HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat. Struct. Mol. Biol. 20 (2013), 90–98.
38. Muller-Hilke, B., Mitchison, N.A., The role of HLA promoters in autoimmunity. Curr. Pharm. Des. 12 (2006), 3743–3752.
39. Atkins, D., Ferrone, S., Schmahl, G.E., Storkel, S., Seliger, B., Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?. J. Urol. 171 (2004), 885–889.
40. Ehsan, S., Amirzargar, A., Yekaninejad, M.S., Mahmoudi, M., Mehravar, S., Moradi, B., Nafissi, S., Association of HLA class II (DRB1, DQA1, DQB1) alleles and haplotypes with myasthenia gravis and its subgroups in the Iranian population. J. Neurol. Sci. 359 (2015), 335–342.
41. Vandiedonck, C., Giraud, M., Garchon, H.J., Genetics of autoimmune myasthenia gravis: the multifaceted contribution of the HLA complex. J. Autoimmun. 25:Suppl (2005), 6–11.
42. Hajeer, A.H., Sawidan, F.A., Bohlega, S., Saleh, S., Sutton, P., Shubaili, A., Tahan, A.A., Al Jumah, M., HLA class I and class II polymorphisms in Saudi patients with myasthenia gravis. Int. J. Immunogenet. 36 (2009), 169–172.
43. Bartoccioni, E., Scuderi, F., Augugliaro, A., Chiatamone Ranieri, S., Sauchelli, D., Alboino, P., Marino, M., Evoli, A., HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 72 (2009), 195–197.